Lucid Diagnostics CEO and Executives Snap Up 5.8 Million Restricted Shares as VA Contract Fuels Insider Optimism—Stock Remains Flat at $1.43.
CEO and insider buying spike at Lucid Diagnostics after VA contract win—insider confidence hints at future upside, but valuation remains low.
3 minutes to read